In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 690 ( 2023-04-05)
Abstract:
p53 is a tumor suppressor that is variably mutated across many cancer types and represents an ideal target for therapeutic rescue. Although each of these mutations inactivates p53, they do so through diverse mechanisms, making each mutation rescuable to a different degree, which has not been studied. To elucidate this, Song et al . have evaluated the 800 most frequent p53 mutations for their ability to be rescued by aresenic trioxide (ATO). They found that solvent accessibility and temperature sensitivity were key determinants of the rescue potential of mutant p53 by ATO and created a classification for p53 mutations that may benefit from this therapy. —DH
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abn9155
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Bookmarklink